Azurrx Biopharma Inc (AZRX) Forecast, Price Target & Analyst Ratings
NASDAQ:AZRX
3.45
+0.07 (+2.07%)
At close: Sep 21, 2021
3.42
-0.03 (-0.87%)
After Hours: 9/21/2021, 8:00:01 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for Azurrx Biopharma Inc (AZRX).
Forecast Snapshot
Consensus Price Target
$3.40
-1.45% Downside
Next Earnings Forecast
Release DateN/A
PeriodQ3 / 2021
EPS Estimate-$0.08
Revenue Estimate
ChartMill Buy Consensus
90.00%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$3.40
Upside
-1.45%
From current price of $3.45 to mean target of $3.40, Based on 4 analyst forecasts
Low
$2.02
Median
$3.06
High
$5.25
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
4 analysts have analysed AZRX and the average price target is 3.4 null. This implies a price decrease of -1.45% is expected in the next year compared to the current price of 3.45.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
90.00%
AZRX was analyzed by 4 analysts. The buy percentage consensus is at 90. So analysts seem to be very confident about AZRX.
In the previous month the buy percentage consensus was at a similar level.
Only 4 analysts analyzed AZRX. So this is just the average opinion of a couple of analysts.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2021-08-02 | HC Wainwright & Co. | Maintains | Buy |
| 2021-04-01 | Roth Capital | Maintains | Buy |
| 2021-04-01 | HC Wainwright & Co. | Maintains | Buy |
| 2021-02-10 | HC Wainwright & Co. | Maintains | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateN/A
PeriodQ3 / 2021
EPS Estimate-$0.08
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q55.00%
Number of Analysts6
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A 3.45% | N/A 5.00% | |
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | -1.05 65.10% | -0.90 14.29% | -0.73 19.07% | -0.85 -16.69% | N/A 52.24% | N/A 27.76% | N/A 28.10% | N/A -25.43% | N/A |
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q3 / 21 | Q4 / 21 | Q1 / 22 | Q2 / 22 | Q3 / 22 | Q4 / 22 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.08 55.00% | -0.08 75.32% | -0.07 49.00% | -0.06 61.75% | -0.06 20.00% | -0.06 20.00% |
| Revenue Q2Q % growth | N/A | N/A | N/A | |||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
20.55%
EPS Next 5 Year
11.05%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
Azurrx Biopharma Inc / AZRX Forecast FAQ
Can you provide the average price target for Azurrx Biopharma Inc stock?
4 analysts have analysed AZRX and the average price target is 3.4 null. This implies a price decrease of -1.45% is expected in the next year compared to the current price of 3.45.
Can you provide the consensus estimates for Azurrx Biopharma Inc next earnings?
The consensus EPS estimate for the next earnings of Azurrx Biopharma Inc (AZRX) is -0.08 null and the consensus revenue estimate is 0 null.
Can you provide the analyst count for Azurrx Biopharma Inc stock?
The number of analysts covering Azurrx Biopharma Inc (AZRX) is 4.